Merrimack Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Merrimack Pharmaceuticals generated cash of -$1,522,000, which is more than the previous year. Cash used in financing activities reached the amount of $521,000 last year. Net change in cash is therefore -$13,450,000.
Cash Flow
| 2014 | -34.80M | -6.01M | 11.42M |
|---|---|---|---|
| 2015 | -105.35M | 75.11M | 180.16M |
| 2016 | -170.24M | -3.25M | 9.41M |
| 2017 | -145.93M | 576.89M | -359.03M |
| 2018 | -65.58M | -22.59M | 14.63M |
| 2019 | -31.36M | 69.82M | -42.54M |
| 2020 | -4.62M | 2.13M | -56K |
| 2021 | -218K | 144K | 239K |
| 2022 | -1.74M | 445K | 6.53M |
| 2023 | -1.52M | -12.44M | 521K |
MACK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 19.43M | 14.20M | 14.03M | 16.58M | 20.66M | 94.21M | 21.52M | 185.60M | 35.68M | 65.08M |
Operating activities | ||||||||||
Net income | -1.18M | -1.54M | -2.45M | -3.02M | -21.26M | -60.93M | -58.72M | -153.51M | -147.78M | -83.55M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 2.22M | 4.07M | 5.22M | 6.24M | 4.28M | 3.22M |
Stock-based compensation expense | 160K | 71K | 397K | 1.72M | 2.37M | 0 | 12.78M | 14.86M | 15.35M | 13.19M |
| Deferred income tax benefit | 160K | 71K | 397K | 1.72M | 2.37M | 0 | 12.78M | 14.86M | 15.35M | 13.19M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 100K | 175K | -10.98M | -3.17M | 2.58M |
Inventories | 0 | 0 | 0 | 0 | 0 | -993K | -8.47M | -9.68M | -3.71M | 827K |
Accounts payable | -148K | 27K | -208K | -1.94M | -12.08M | -3.80M | -9.27M | -3.86M | 13.55M | -646K |
Cash generated by operating activities | -1.52M | -1.74M | -218K | -4.62M | -31.36M | -65.58M | -145.93M | -170.24M | -105.35M | -34.80M |
Investing activities | ||||||||||
Purchases Of Investments | -18.58M | 0 | 0 | 0 | 0 | -103.05M | 0 | -84.26M | 0 | -111.83M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | -118K | -915K | -3.15M | -12.78M | -6.03M |
Acquisitions Net | 0 | 0 | 0 | 0 | 7.8M | 28.07M | -4.00M | 3.25M | 0 | 0 |
Cash generated by investing activities | -12.44M | 445K | 144K | 2.13M | 69.82M | -22.59M | 576.89M | -3.25M | 75.11M | -6.01M |
Financing activities | ||||||||||
Common Stock Issued | 521K | 6.53M | 239K | 0 | 145K | 0 | 3.99M | 3.36M | 38.56M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -26.7M | 0 | -140M | 0 | 0 | -7K |
Repurchases of common stock | 0 | 0 | 0 | 0 | -145K | 0 | 6.91M | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -14.63M | 0 | 0 | 0 | -1.04K |
Cash used in financing activities | 521K | 6.53M | 239K | -56K | -42.54M | 14.63M | -359.03M | 9.41M | 180.16M | 11.42M |
Net Change In Cash | -13.45M | 5.23M | 165K | -2.54M | -4.08M | -73.55M | 71.91M | -164.08M | 149.91M | -29.39M |
Cash at end of period | 5.98M | 19.43M | 14.20M | 14.03M | 16.58M | 20.66M | 93.44M | 21.52M | 185.60M | 35.68M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |